Active, Not Recruiting
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
NCT03805932
- Conditions
- Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States